glp 1 compounding pharmacy lawsuit Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Deceptive information and online sales

On Monday, 24th November, Novo Nordisk published a press release, explaining that the Evoke and Evoke+ trials did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimers disease. Although the researchers did report significant reductions in biomarkers associated with Alzheimers, there was no reduction in disease progression in either trial

10.1016/j.biopsych.2012.01.035 21 De JongheB

Works fantastically

The latest generation of Pico lasers can markedly improve melasma within a few treatment sessions, whilst novel chemical peels can quickly, effectively & safely remove melasma pigment in most patients

Journal of Obstetrics and Gynaecology

Were excited to introduce LDN as a complementary drug to GLP-1 treatments